These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 34041034)

  • 1. Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma.
    Frederico SC; Hancock JC; Brettschneider EES; Ratnam NM; Gilbert MR; Terabe M
    Front Oncol; 2021; 11():672508. PubMed ID: 34041034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.
    Trivedi V; Yang C; Klippel K; Yegorov O; von Roemeling C; Hoang-Minh L; Fenton G; Ogando-Rivas E; Castillo P; Moore G; Long-James K; Dyson K; Doonan B; Flores C; Mitchell DA
    Genome Med; 2024 Jan; 16(1):17. PubMed ID: 38268001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
    Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
    J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier.
    Frederico SC; Darling C; Bielanin JP; Dubinsky AC; Zhang X; Hadjipanayis CG; Kohanbash G
    Front Immunol; 2023; 14():1057567. PubMed ID: 36875096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
    Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
    J Big Data; 2022; 9(1):92. PubMed ID: 35855914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
    Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
    Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Immunotherapeutic Strategies for the Treatment of Glioblastoma.
    Dapash M; Castro B; Hou D; Lee-Chang C
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials.
    Srivastava S; Jackson C; Kim T; Choi J; Lim M
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30991681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions.
    Fathi M; Razavi SM; Sojoodi M; Ahmadi A; Ebrahimi F; Namdar A; Hojjat-Farsangi M; Gholamin S; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2022 Nov; 26(11):949-961. PubMed ID: 36527817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
    Wang C; Yu M; Zhang W
    Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current approaches in glioblastoma multiforme immunotherapy.
    Aghajani M; Jalilzadeh N; Aghebati-Maleki A; Yari A; Tabnak P; Mardi A; Saeedi H; Aghebati-Maleki L; Baradaran B
    Clin Transl Oncol; 2024 Jul; 26(7):1584-1612. PubMed ID: 38512448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.